Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||||||||
Cash from operating activities | -81.69%383M | 41.28%34.98B | -27.78%12.81B | 405.27%11.89B | -13.09%8.19B | 143.98%2.09B | -20.05%24.76B | 92.51%17.74B | -82.44%2.35B | -34.51%9.43B |
Net profit before non-cash adjustment | 9.92%8.77B | 5.57%29.4B | -29.17%4.6B | 14.43%9.05B | 26.67%7.77B | 9.12%7.98B | -1.92%27.85B | 15.35%6.49B | 3.93%7.91B | -15.98%6.13B |
Total adjustment of non-cash items | -385.87%-789M | 10.27%7.54B | 52.24%5.14B | 62.05%1.47B | -72.13%645M | 18.45%276M | 27.01%6.83B | 5.76%3.38B | 4.60%909M | 96.60%2.31B |
-Depreciation and amortization | -1.53%1.61B | 13.97%6.55B | 7.53%1.64B | 12.62%1.63B | 13.43%1.64B | 23.44%1.64B | 4.81%5.75B | 9.93%1.53B | 5.99%1.45B | 5.78%1.45B |
-Reversal of impairment losses recognized in profit and loss | ---- | --639M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
-Disposal profit | -232.86%-466M | ---140M | --0 | --0 | --0 | ---140M | --0 | --0 | --0 | --0 |
-Other non-cash items | -58.43%-1.94B | -55.40%483M | 54.62%2.86B | 70.43%-160M | -214.38%-994M | -11.70%-1.22B | 1,240.00%1.08B | 2.38%1.85B | -8.85%-541M | 559.79%869M |
Changes in working capital | -23.23%-7.6B | 80.32%-1.95B | -61.04%3.07B | 121.26%1.37B | -122.89%-225M | 49.90%-6.17B | -254.52%-9.92B | 1,907.14%7.87B | -231.34%-6.46B | -83.39%983M |
-Change in receivables | -4.85%-10.43B | 62.45%-4.6B | -44.24%9.46B | 100.72%86M | 22.89%-4.2B | 15.34%-9.94B | -339.83%-12.25B | 140.26%16.97B | -3,322.79%-12.02B | -1,217.21%-5.45B |
-Change in inventory | -44.43%-3.11B | 97.63%-78M | 8.45%13.98B | 4.48%-12.47B | 114.40%569M | -358.89%-2.15B | -47.60%-3.29B | 78.28%12.89B | -61.53%-13.05B | -679.49%-3.95B |
-Change in payables | 2.52%5.26B | -70.10%1.82B | 3.66%-21.84B | -25.09%14.54B | -64.91%3.99B | 352.39%5.13B | 175.61%6.09B | -49.36%-22.67B | 44.73%19.41B | 61.78%11.38B |
-Provision for loans, leases and other losses | -15.14%684M | 290.32%904M | 115.74%1.47B | 1.87%-787M | 41.27%-582M | 26.33%806M | -11,975.00%-475M | -46.79%680M | -2.04%-802M | 9.66%-991M |
Dividends paid (cash flow from operating activities) | ||||||||||
Dividends received (cash flow from operating activities) | ||||||||||
Interest paid (cash flow from operating activities) | -2M | 40.00%-3M | 40.00%-3M | 0 | 0 | 0 | 16.67%-5M | 16.67%-5M | 0 | 0 |
Interest received (cash flow from operating activities) | 16.23%179M | 16.62%449M | 5.19%81M | 12.12%111M | 33.77%103M | 16.67%154M | 1.85%385M | 10.00%77M | 6.45%99M | -1.28%77M |
Tax refund paid | -18.73%-4.96B | -0.19%-8.4B | 0 | 1.12%-4.22B | 0 | -1.55%-4.18B | 10.31%-8.39B | 0 | 3.50%-4.27B | 0 |
Other operating cash inflow (outflow) | -4,500.00%-44M | -47.50%-236M | -148.26%-236M | 101.56%1M | 99.06%-2M | 100.27%1M | -280.95%-160M | 49,000.00%489M | -966.67%-64M | -213.30%-213M |
Operating cash flow | -129.99%-4.45B | 61.44%26.79B | -30.86%12.65B | 513.06%7.78B | -10.73%8.29B | 78.78%-1.93B | -24.40%16.59B | 97.25%18.3B | -120.79%-1.88B | -36.62%9.29B |
Investing cash flow | ||||||||||
Net PPE purchase and sale | 92.94%-319M | -2.09%-5.67B | -228.00%-656M | 76.72%-261M | 94.43%-233M | -10,163.64%-4.52B | 39.18%-5.55B | 80.49%-200M | 50.79%-1.12B | 10.21%-4.19B |
Net intangibles purchase and sale | -38.46%-36M | 38.12%-138M | 36.96%-29M | -34.15%-55M | 40.43%-28M | 70.79%-26M | 22.57%-223M | 40.26%-46M | 54.44%-41M | 54.81%-47M |
Net business purchase and sale | ---- | -25.23%-139M | ---139M | ---- | ---- | ---- | ---111M | --0 | ---- | ---- |
Net investment product transactions | 109.44%488M | -315.79%-316M | -4,422.22%-407M | -348.28%-130M | -9.09%-12M | 962.96%233M | -130.30%-76M | -111.54%-9M | -178.38%-29M | 92.25%-11M |
Net changes in other investments | -50.00%-3M | 93.23%-9M | ---- | ---- | --0 | -116.67%-2M | 81.63%-133M | 96.74%-22M | -526.67%-94M | -93.33%-29M |
Investing cash flow | 103.02%130M | -2.87%-6.27B | -347.65%-1.24B | 68.19%-444M | 93.61%-273M | -2,812.84%-4.31B | 40.09%-6.09B | 83.69%-277M | 40.49%-1.4B | 13.21%-4.27B |
Financing cash flow | ||||||||||
Net common stock issuance | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Increase or decrease of lease financing | -11.11%-30M | 22.15%-116M | 34.21%-25M | 13.89%-31M | 10.81%-33M | 28.95%-27M | -10.37%-149M | 0.00%-38M | 7.69%-36M | -27.59%-37M |
Cash dividends paid | -19.29%-3.07B | -7.50%-5.4B | -50.00%-3M | -9.71%-2.83B | -25.00%-5M | -5.11%-2.57B | -5.48%-5.03B | 33.33%-2M | -4.00%-2.58B | 0.00%-4M |
Net other fund-raising expenses | ---- | ---- | ---- | --0 | --1M | -100.00%-2M | 0.00%-1M | --1M | ---1M | --0 |
Financing cash flow | -19.12%-3.1B | -6.63%-5.52B | 30.77%-27M | -9.34%-2.86B | 9.76%-37M | -4.63%-2.6B | 40.71%-5.18B | 62.86%-39M | 56.80%-2.61B | 52.33%-41M |
Net cash flow | ||||||||||
Beginning cash position | 32.62%60.99B | 13.09%45.99B | 77.12%49.61B | 33.13%45.13B | 28.44%37.15B | 13.09%45.99B | 8.10%40.67B | -15.63%28.01B | 4.21%33.9B | 26.41%28.92B |
Current changes in cash | 16.17%-7.42B | 181.78%15B | -36.69%11.39B | 176.01%4.48B | 60.40%7.98B | 24.70%-8.85B | 74.67%5.32B | 140.60%17.99B | -985.86%-5.89B | -48.42%4.98B |
Cash adjustments other than cash changes | 50.00%-1M | 0.00%-1M | --0 | --0 | --1M | -100.00%-2M | 0.00%-1M | --0 | ---- | ---- |
End cash Position | 44.24%53.58B | 32.62%60.99B | 32.62%60.99B | 77.12%49.61B | 33.13%45.13B | 28.44%37.15B | 13.09%45.99B | 13.09%45.99B | -15.63%28.01B | 4.21%33.9B |
Free cash flow | 25.83%-4.8B | 93.94%20.99B | -33.71%11.97B | 345.06%7.46B | 58.80%8.03B | 29.97%-6.48B | -13.68%10.82B | 120.83%18.06B | -145.52%-3.05B | -48.87%5.06B |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |